Novartis signs deal for Arvinas’ prostate cancer therapy

Novartis has signed an exclusive strategic licence agreement for Arvinas’ ARV-766, a new treatment for prostate cancer.

Apr 13, 2024 - 00:00

Novartis signs deal for Arvinas’ prostate cancer therapy

Novartis has signed an exclusive strategic licence agreement for Arvinas’ ARV-766, a new treatment for prostate cancer.

Read the original article

Tags:

Previous Article

Eliem Therapeutics agrees to acquire Tenet

FDA approves AstraZeneca’s FASENRA for asthma in children

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Can the government ask social media sites to take down Covid misinformation? SCOTUS will weigh in

Can the government ask social media sites to take down ...

Jan 30, 2024

STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion

STAT+: Bristol Myers to purchase Karuna, maker of schiz...

Dec 23, 2023

UKHSA signs influenza vaccine deal with CSL Seqirus

UKHSA signs influenza vaccine deal with CSL Seqirus

Sep 27, 2023